Anthony F. Shields

19.4k total citations · 3 hit papers
360 papers, 11.9k citations indexed

About

Anthony F. Shields is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Anthony F. Shields has authored 360 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Oncology, 94 papers in Pulmonary and Respiratory Medicine and 88 papers in Cancer Research. Recurrent topics in Anthony F. Shields's work include Colorectal Cancer Treatments and Studies (86 papers), Pancreatic and Hepatic Oncology Research (60 papers) and Medical Imaging Techniques and Applications (56 papers). Anthony F. Shields is often cited by papers focused on Colorectal Cancer Treatments and Studies (86 papers), Pancreatic and Hepatic Oncology Research (60 papers) and Medical Imaging Techniques and Applications (56 papers). Anthony F. Shields collaborates with scholars based in United States, Canada and Japan. Anthony F. Shields's co-authors include John R. Grierson, Barry A. Siegel, Philip A. Philip, Thomas J. Mangner, Otto Muzik, R. Edward Coleman, Jawana M. Lawhorn‐Crews, David Baltimore, Mark M. Zalupski and James R. Bading and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Anthony F. Shields

342 papers receiving 11.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography

1998 938 citations Anthony F. Shields, Jawana M. Lawhorn‐Crews et al. profile →
Recommendations on the Use of ¹⁸F-FDG PET in Oncology

2008 790 citations Barry A. Siegel, R. Edward Coleman et al. profile →
The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions

2016 230 citations Anthony F. Shields et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Anthony F. Shields

Since Specialization

Citations

This map shows the geographic impact of Anthony F. Shields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony F. Shields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony F. Shields more than expected).

Fields of papers citing papers by Anthony F. Shields

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony F. Shields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony F. Shields. The network helps show where Anthony F. Shields may publish in the future.

Co-authorship network of co-authors of Anthony F. Shields

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony F. Shields. A scholar is included among the top collaborators of Anthony F. Shields based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony F. Shields. Anthony F. Shields is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study 2025 ·PubMed ·Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M. Bauer, David L. Bajor, Anthony Elias, Anthony F. Shields, Elizabeth J. Davis, Sant P. Chawla, (unknown), John D. Powderly, Gina Z. D’Amato, Christian F. Meyer, Xiongwen Tang, Sheng Yao, Patricia Keegan	0
2	Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance) 2025 ·JNCI Journal of the National Cancer Institute ·En Cheng, Qian Shi, Anthony F. Shields, Xiaonan Xue, Thomas E. Rohan, Chaoyuan Kuang, (unknown), (unknown), (unknown), J. Philip Kuebler, (unknown), Benjamin Kye Jyn Tan, Smitha Krishnamurthi, Kimmie Ng, Eileen M. O’Reilly, Justin C. Brown, Jeffrey A. Meyerhardt	0
3	Uncovering actionable genetic alterations and immune predictive biomarkers for anal squamous cell carcinomas in the era of immunotherapy: PD-L1 and beyond. 2024 ·Journal of Clinical Oncology ·(unknown), Yasmine Baca, Joanne Xiu, Alex Farrell, George W. Sledge, Anwaar Saeed, Anthony F. Shields, (unknown), Sanjay Goel, Benjamin A. Weinberg, Emil Lou	1
4	Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Joshua Millstein, Joanne Xiu, Shivani Soni, (unknown), (unknown), (unknown), Jae Ho Lo, (unknown), Priya Jayachandran, Wu Zhang, Anthony F. Shields, Richard M. Goldberg, Emil Lou, Benjamin A. Weinberg, John L. Marshall, Aaron S. Meyer, Francesca Battaglin, Heinz‐Josef Lenz	1
5	Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets 2024 ·JCO Precision Oncology ·Erik B. Faber, (unknown), (unknown), (unknown), Peter J. Hosein, Anthony F. Shields, Heinz‐Josef Lenz, (unknown), Sanjay Goel, Matthew J. Oberley, Giuseppe Malleo, Claudio Luchini, Justin H. Hwang, Vaia Florou, Ignacio Garrido‐Laguna, Emil Lou	3
6	Association between physical activity and the time course of cancer recurrence in stage III colon cancer 2023 ·British Journal of Sports Medicine ·Justin C. Brown, (unknown), Qian Shi, Donna Niedzwiecki, Tyler Zemla, Félix Couture, Philip Kuebler, Pankaj Kumar, Judith O. Hopkins, Benjamin Kye Jyn Tan, Smitha Krishnamurthi, Eileen M. O’Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt	19
7	Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers 2023 ·Molecular Cancer Therapeutics ·Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, (unknown), Md. Hafiz Uddin, (unknown), (unknown), Ibrahim Azar, Eliza W. Beal, (unknown), Steve Kim, (unknown), Erkan Baloglu, William Senapedis, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Mohammed Najeeb Al Hallak, Asfar S. Azmi	5
8	Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702 2022 ·Journal of Clinical Oncology ·Seohyuk Lee, (unknown), Qian Shi, Pankaj Kumar, Félix Couture, Philip Kuebler, Smitha Krishnamurthi, DeQuincy Andrew Lewis, Benjamin Kye Jyn Tan, Richard M. Goldberg, Alan P. Venook, Charles D. Blanke, Eileen M. O’Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt	10
9	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers 2022 ·Cancer Research Communications ·Husain Yar Khan, Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton, (unknown), (unknown), Mohammed Najeeb Al Hallak, Steve Kim, (unknown), Yosef Landesman, Hirva Mamdani, Dipesh Uprety, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Asfar S. Azmi	21
10	Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) 2022 ·Journal of Clinical Oncology ·Justin C. Brown, (unknown), Qian Shi, Charles S. Fuchs, (unknown), Donna Niedzwiecki, Tyler Zemla, Félix Couture, Philip Kuebler, Pankaj Kumar, DeQuincy Andrew Lewis, Benjamin Kye Jyn Tan, Smitha Krishnamurthi, Eileen M. O’Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt	24
11	Molecular Characterization of Appendiceal Goblet Cell Carcinoid 2020 ·Molecular Cancer Therapeutics ·Hiroyuki Arai, Yasmine Baca, Francesca Battaglin, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Joshua Millstein, Curtis Johnston, Richard M. Goldberg, Philip A. Philip, Andreas Seeber, Joanne Xiu, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, W. Michael Korn, Heinz‐Josef Lenz	18
12	Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer 2020 ·Clinical Cancer Research ·Jim Abraham, Daniel Magee, Chiara Cremolini, Carlotta Antoniotti, (unknown), Joanne Xiu, Phillip Stafford, Donald A. Berry, Matthew J. Oberley, Anthony F. Shields, John L. Marshall, Mohamed E. Salem, Alfredo Falcone, Axel Grothey, Michael J. Hall, Alan P. Venook, Heinz‐Josef Lenz, (unknown), W. Michael Korn, David Spetzler	35
13	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma 2020 ·Journal of Surgical Oncology ·Matthew K. Stein, (unknown), Joanne Xiu, (unknown), Michael G. Martin, (unknown), Paxton V. Dickson, Evan S. Glazer, Danny Yakoub, David Shibata, Axel Grothey, Philip A. Philip, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, W. Michael Korn, Heinz‐Josef Lenz, Jeremiah L. Deneve	18
14	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer 2019 ·Clinical Cancer Research ·Ryuma Tokunaga, Joanne Xiu, Curtis Johnston, Richard M. Goldberg, Philip A. Philip, Andreas Seeber, Madiha Naseem, Jae Ho Lo, Hiroyuki Arai, Francesca Battaglin, Alberto Puccini, Martin D. Berger, Shivani Soni, Wu Zhang, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, Hideo Baba, W. Michael Korn, Heinz‐Josef Lenz	62
15	The current state of molecular testing in the treatment of patients with solid tumors, 2019 2019 ·CA A Cancer Journal for Clinicians ·Wafik S. El‐Deiry, Richard M. Goldberg, Heinz‐Josef Lenz, Anthony F. Shields, Geoffrey T. Gibney, Antoinette R. Tan, Jubilee Brown, Burton Eisenberg, Elisabeth I. Heath, Surasak Phuphanich, Edward Kim, Andrew Brenner, John L. Marshall	187
16	Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer 2018 ·Clinical Cancer Research ·Ulka N. Vaishampayan, Izabela Podgorski, Lance K. Heilbrun, Jawana M. Lawhorn‐Crews, (unknown), Julie L. Boerner, (unknown), Daryn Smith, Elisabeth I. Heath, Joseph A. Fontana, Anthony F. Shields	3
17	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers 2018 ·Molecular Cancer Research ·Mohamed E. Salem, Alberto Puccini, Axel Grothey, Derek Raghavan, Richard M. Goldberg, Joanne Xiu, W. Michael Korn, Benjamin A. Weinberg, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, Philip A. Philip, Heinz‐Josef Lenz	159
18	Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer. 2017 ·PubMed ·(unknown), Anthony F. Shields, Jimmy J. Hwang, Raymond Wadlow, John L. Marshall	3
19	Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry 2008 ·Journal of Clinical Oncology ·Bruce E. Hillner, Barry A. Siegel, Dawei Liu, Anthony F. Shields, Ilana F. Gareen, Lucy Hanna, Sharon Hartson Stine, R. Edward Coleman	269
20	In Vivo Imaging of Cancer Therapy 2007 ·Humana Press eBooks ·Anthony F. Shields, Pat Price	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact